Genetic polymorphism at BCL2 as a predictor for rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma.
about
Genetic polymorphism at BCL2 as a predictor for rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Genetic polymorphism at BCL2 a ...... diffuse large B-cell lymphoma.
@en
Genetic polymorphism at BCL2 a ...... diffuse large B-cell lymphoma.
@nl
type
label
Genetic polymorphism at BCL2 a ...... diffuse large B-cell lymphoma.
@en
Genetic polymorphism at BCL2 a ...... diffuse large B-cell lymphoma.
@nl
prefLabel
Genetic polymorphism at BCL2 a ...... diffuse large B-cell lymphoma.
@en
Genetic polymorphism at BCL2 a ...... diffuse large B-cell lymphoma.
@nl
P2093
P2860
P50
P1433
P1476
Genetic polymorphism at BCL2 a ...... diffuse large B-cell lymphoma.
@en
P2093
Angela R Brooks-Wilson
Barbara Meissner
Brian R Berry
Graham W Slack
Johanna M Schuetz
John J Spinelli
Laurie H Sehn
Morteza Bashash
Stephen Leach
P2860
P304
P356
10.3324/HAEMATOL.2016.159087
P577
2017-02-02T00:00:00Z